重组带状疱疹(GlaxoSmithKline Plc)(Zoster vaccine recombinant, adjuvanted(GlaxoSmithKline Plc)) - 在研适应症：疱疹后神经痛，带状疱疹，呼吸道合胞体病毒感染_专利_临床

概要

基本信息

药物类型

预防性疫苗、重组亚单位疫苗

别名

herpes zoster vaccine (recombinant, adjuvanted)、HZ/su、PED-HZ/su

+ [18]

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染神经系统疾病其他疾病+ [2]

在研适应症

疱疹后神经痛带状疱疹呼吸道合胞体病毒感染+ [3]

非在研适应症

慢性淋巴细胞白血病新型冠状病毒感染白喉+ [7]

原研机构

GSK Plc

在研机构

GSK PlcGlaxoSmithKline Biologicals SAGlaxoSmithKline, Inc.

+ [4]

非在研机构-

最高研发阶段批准上市

首次获批日期

加拿大 (2017-10-13),

带状疱疹

最高研发阶段(中国)批准上市

特殊审评临床急需境外新药 (中国)

登录后查看时间轴

结构/序列

Sequence Code 13420648

关联

86

项与重组带状疱疹(GlaxoSmithKline Plc) 相关的临床试验

NCT06890416

/ Recruiting临床3期

A PHASE 3, MULTICENTER, PARALLEL-GROUP, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS ≥50 YEARS OF AGE

This purpose of this phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.

开始日期2025-04-04

申办/合作机构

Pfizer Inc.

NCT06763783

/ Enrolling by invitation临床4期

Vaccination in Patients With Inflammatory Rheumatic Diseases. The Impact of Anti-rheumatic Treatments on the Immunogenicity of Herpes-zoster Vaccine (Shingrix) and Protection Against Infection (HZ-REUMA)

The purpose of HZ-REUMA study is explore vaccine response and protection against shingles (herpes zoster, HZ) after vaccination with two doses of Shingrix in immunosuppressed patients with inflammatory rheumatic diseases (IRD) compared to immunocompetent patients with IRD (controls).
Hypothesis:
The immunological disturbance as part of the rheumatic disease in combination with different immunomodulating treatments may impair vaccine response to non-live HZ vaccine (Shingrix) and thereby lead to an insufficient protection against infection.
Primary objective (outcome)
1. The impact of modern anti-rheumatic treatments including synthetic disease modifying anti-rheumatic drugs (DMARDs) such as methotrexate and different biological treatments (anti-TNF, anti IL6r, anti-IL12/23/17, anti-CD20, anti-BlyS, anti-INFERON treatment, or targeted DMARDs (JAK-inhibitors) on antibody response elicited by two doses of subunit vaccine against herpes zoster (HZ) administrated 1-2 months apart in patients with IRD.
Secondary outcomes
2. The numbers and frequency of antigen specific CD4 2+ T cells expressing ≥2 or more activation markers (TNFalpha, INF-gama, interleukin-2 or CD40ligand)
3. Long-term immunogenicity of two doses of Shingrix in immunosuppressed patients with IRD measured 3 and 5 after vaccination
4. the tolerability of the vaccine, the impact on existing rheumatic disease, and possible association with onset of new autoimmune diseases
5. if vaccination against herpes zoster protects against infections in patients with inflammatory rheumatic diseases
Study Population Adult patients (18 years and older) with a clinically diagnosed inflammatory rheumatic disease and regularly followed at Skåne University Hospital, section for rheumatology in Lund/Malmö, Sweden are eligible for the study and will be offered vaccination free of charge. Control group comprises adult individuals with known inflammatory rheumatic disease without immunosuppressive treatment except for low dose prednisone (max 5 mg daily) .
Inclusion criteria:
* age ≥18 years (patients)
* regular follow up at Skåne University Hospital, section for rheumatology Lund/Malmö due to an inflammatory rheumatic disease (patients)
* receive active treatment with disease modifying anti-rheumatic drugs (DMARDs) such conventional synthetic (cs), biologic (b) or targeted synthetic (ts) DMARDs or patients without active immunosuppressive treatment (controls)
Exclusions criteria
* age <18 years (patients)
* pregnancy (women of childbearing potential, WOCBP, are not excluded since all patients using DMARDs are advised to use a safe and effective contraceptive method)
* allergy/intolerability of any component in the vaccine
* active infection inclusive herpes zoster (shingles)
* received Shingrix vaccine previously
* ongoing treatment with any immunosuppressive drug for the other diseases Target enrolment/sample size: 240. Study start date: December, 17 2024- June 30, 2029

开始日期2024-12-17

申办/合作机构

Region Skåne Holding AB

ChiCTR2400090653

/ Suspended临床1期IIT

Clinical study on the protective mechanism of immune response of recombinant herpes zoster vaccine (CHO cell) based on multi-omics

开始日期2024-10-15

申办/合作机构-

100 项与重组带状疱疹(GlaxoSmithKline Plc) 相关的临床结果

登录后查看更多信息

100 项与重组带状疱疹(GlaxoSmithKline Plc) 相关的转化医学

登录后查看更多信息

100 项与重组带状疱疹(GlaxoSmithKline Plc) 相关的专利（医药）

登录后查看更多信息

3,830

项与重组带状疱疹(GlaxoSmithKline Plc) 相关的文献（医药）

2025-12-31·Global Public Health

An intersectional analysis of social constraints and agency among sex workers in Tunisia during the COVID-19 pandemic; the community-based qualitative study EPIC-MENA

Article

作者: Bourhaba, Othmane ; Lorente, Nicolas ; Adami, Elisa ; Nabli, Montassar ; Karkouri, Mehdi ; Boulahdour, Nassima ; Torkhani, Sonia ; Beldi Chouikha, Khawla ; Castro Avila, Juliana ; Rojas Castro, Daniela ; Di Ciaccio, Marion

The economic, social and health impacts of the COVID-19 pandemic varied across population groups. This study aimed to provide a comprehensive view of the effects of socioeconomic constraints on sex workers' agency during the COVID-19 pandemic in Tunisia, using the analytical framework of intersectionality. We performed a thematic content analysis of semi-structured interviews conducted with sex workers (n = 19). Results highlighted the heavy burden of socioeconomic constraints on their agency, and specifically on their decision to continue sex work or not during the pandemic. The fact that there were fewer clients during the pandemic led to greater economic precarity, especially among mothers. Furthermore, interviewees - mostly cisgender male sex workers with same-sex practices - reported increased violence and discrimination by clients and the police. Participants also experienced difficulties accessing health care for themselves and for their children, including access to COVID-19 vaccination. This was especially true for women with a low educational level. Finally, sex workers' mental health was also strongly affected by the pandemic. Findings highlights the role of various intersecting socioeconomic conditions and structural vulnerabilities on sex workers' experience of the COVID-19 pandemic in Tunisia, in terms of health and their capacity to negotiate agency.

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

Characterizing the clinical and economic burden of COVID-19 among individuals with immunocompromising conditions in Ontario, Canada – a matched, population-based observational study

Article

作者: Nam, Austin ; Johnston, Karissa M. ; Tinajero, Maria ; Voss, M. Lauren ; Hamilton, Mackenzie A. ; Qian, Christina

AIMS:

COVID-19 continues to be associated with substantial burden among immunocompromised patients (IC). This study aimed to describe and compare outcomes during and following COVID-19 hospitalizations among IC and non-IC patients.

METHODS:

Patients hospitalized with COVID-19 (January 2020-March 2023) were identified in Ontario health administrative claims databases. All eligible IC (≥1 of solid organ or stem cell transplant; hematological malignancy; rheumatoid arthritis; multiple sclerosis; or primary immunodeficiency) were matched (1:4) to eligible non-IC. Clinical, resource, and costburden were assessed during and post-hospitalization. Multivariate regression models were used to estimate relative risks (RRi), rates (RRa), and corresponding 95% confidence intervals (CIs), adjusting for neighborhood deprivation, long-term care residency, baseline comorbidities, and COVID-19 vaccination status.

RESULTS:

9,283 IC hospitalized (mean age 68.7 years; 52.1% female) were matched to 37,127 non-IC. During index hospitalization, IC had greater risks of intensive care unit admission (RRi = 1.06 [1.01-1.12]), ventilation (RRi = 1.27 [1.19-1.36]), and all-cause mortality (RRi = 1.34 [1.27-1.41]) compared to non-IC. Within 30-days post-discharge, IC had greater rates of all-cause readmission (RRa = 1.33 [1.26-1.40]), emergency departments admission (RRa = 1.13 [1.08-1.18]), home oxygen use (RRi = 1.35 [1.15-1.58]), and COVID-19-related rehabilitation (RRa = 1.52 [1.22-1.89]), resulting in 21% (16%-25%) and 51% (45%-58%) greater costs in hospital and post-discharge, respectively. All-cause mortality remained approximately 5% higher for IC vs. non-IC at 30- and 60-days post-discharge (p < .001). Resource use remained elevated among IC with 57% (50%-64%) greater costs within 180 days post-discharge.

LIMITATIONS:

Unmeasured confounding remains; hospital prescription data were not available such that treatments for COVID-19 were not captured. Attribution of post-discharge resource use and costs to COVID-19 was subject to greater uncertainty further from the index hospitalization.

CONCLUSION:

IC experienced more severe COVID-19 hospitalization outcomes compared to non-IC. COVID-mitigating policies and prophylactic treatments are needed to protect immunocompromised populations.

2025-12-31·Human Vaccines & Immunotherapeutics

Poison, lies, war: A mixed methods content analysis of posts about COVID-19 vaccination on Gab Social

Article

作者: Smith, Andrea M. ; Fritz, Alice Marianne

Recent surges in COVID-19 cases demonstrate the unabated transmissibility of this disease. Despite the ongoing threat of contagion, however, uptake of the COVID-19 vaccines, especially as booster doses, remains suboptimal among eligible adults and children in the United States, as reported by the World Health Organization (WHO). Public attitudes toward these vaccines remain balkanized, with some groups harboring ambivalence or even opposition to receiving inoculation. Given the challenges for public health posed by the current, and potentially, future pandemics, it is crucial to understand more about how laypersons discuss and frame the vaccination debate in informal, non- or minimally monitored spaces. Following their development, virtual groups were created to share stories about negative reactions to COVID-19 vaccines. Using a mixed methods approach, the present study analyzed a census of 368 posts on Gab Social that articulate users' attitudes toward COVID-19 vaccination. Our approach focused on the framing and themes reflected in the posts, along with specific concerns expressed by users. Key findings include the observation that Gab users frequently frame the COVID-19 vaccination decision as one of whether the vaccines do more harm than good (i.e. helping vs. hurting frame) and that adverse reactions to the COVID-19 vaccines are not being truthfully reported on by mainstream media. Moreover, posts often display an antagonistic "Us vs. Them" perspective that pits vaccine skeptics against adherents. Overall, Gab users expressed strong resistance to the vaccines and distrusted government-issued recommendations to vaccinate, yet valorized medical professionals who advocated for more research on the vaccines' safety. Through these investigations, we hope to derive insights that may inform COVID-19 vaccine promotion; accordingly, practical recommendations are suggested based on our findings.

350

项与重组带状疱疹(GlaxoSmithKline Plc) 相关的新闻（医药）

22 小时之前

·Pharmaceutical Technology

UK’s MHRA authorises GSK’s Blenrep for multiple myeloma treatment

GSK’s Blenrep combos are being reviewed in 14 nations. Credit: Magda Wygralak/Shutterstock. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised GSK’s Blenrep for treating multiple myeloma (MM). This authorisation is said to be a global first for Blenrep in this treatment setting. Blenrep, in conjunction with bortezomib and dexamethasone (BVd) is approved for adults who have previously undergone a minimum of one therapy. Additionally, it is approved as the combination with pomalidomide and dexamethasone (BPd) for those who have previously been treated with lenalidomide, among other therapies. The MHRA decision is supported by efficacy outcomes from the Phase III DREAMM-7 and DREAMM-8 trials in relapsed or refractory MM, which demonstrated meaningful progression-free survival (PFS) and overall survival (OS) results. The tolerability and safety profiles of the Blenrep combos align with those of the individual agents involved. Its combos are being reviewed in 14 nations, including the US, Japan, the European Union, China, Switzerland, and Canada. GSK oncology, research and development (R&D) global head and senior vice-president Hesham Abdullah said: “Today’s approval of Blenrep combinations in the UK is a transformative milestone for patients with MM, a cancer marked by remission and relapse. “As the only B-cell maturation antigen (BCMA)-targeted antibody-drug conjugate (ADC) therapy, Blenrep has the potential, supported by robust phase III data, to extend survival and remission versus standard of care and redefine treatment at or after first relapse.” Blenrep consists of an ADC that features a humanised antibody targeting BCMA, attached to the toxic compound auristatin F through a stable linker. The technology for the drug-linker combination is obtained under license from Seagen, while the production of the monoclonal antibody leverages POTELLIGENT Technology licensed from Kyowa Kirin Group’s BioWa. As the only anti-BCMA ADC in MM, the therapy could be administered in various oncology treatment settings. Last month, GSK announced that it is partnering with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to explore if its shingles vaccine, Shingrix, could minimise the dementia risk.

临床结果上市批准临床3期疫苗

2025-04-11

·药时空

最新！智飞生物重组带状疱疹疫苗（CHO细胞）申报临床

根据CDE2025年04月11日显示：安徽智飞龙科马生物制药有限公司重组带状疱疹疫苗（CHO细胞）申报临床，临床试验登记号CXSL2500282，注册分类1.3类。2023 年 10 月重庆智飞生物与葛兰素史克“GSK”签署了《独家经销和联合推广协议》，GSK 将向智飞生物独家供应重组带状疱疹疫苗，并许可智飞生物根据约定在合作区域内营销、推广、进口并经销有关产品。合作期限将从2023年10月8日持续至2026年底，2024年最低采购金额34.4亿元，2025年最低采购金额为68.8亿元，2026年最低采购金额为103.2亿元。合计最低采购金额206.4亿元。2024年12月5日，智飞生物发布关于与GSK优化并调整战略合作的公告。双方延长了带状疱疹疫苗（Shingrix）合作伙伴关系，但供应量有所减少：独家进口、分销和共同推广重组带状疱疹疫苗的权利期限从2026年底延长至2034年底。重组带状疱疹疫苗的预计采购金额约为216亿元。同时将呼吸道合胞病毒（RSV）疫苗的合作向前推进了一步，促成初步为期10年的RSV疫苗商业化合作。关于智飞研发平台和管线围绕九大技术平台，公司形成了结构清晰、布局合理的八大产品矩阵。自主研发项目共计 31 项，其中处于临床试验及申请注册阶段的项目17项，具体情况如下：资料来源：CDE、公告等识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

疫苗带量采购申请上市

2025-04-06

·微信

34%关税冲击波，特朗普医药威胁或引供应链动荡

撰稿 | Paul来自 | 蒲公英Ouryao 4月2日，特朗普宣布对多国实施关税：全球10%的基准关税，外加对特定国家的“互惠”报复性关税——欧洲20%，中国34%，加拿大和墨西哥25%。这波关税如狂风骤雨，却给医药产品开了个“豁免小窗”，至少目前如此。白宫发言人向媒体确认，医药品暂时不在10%基准关税和更高税率的打击范围内。但别高兴太早，行政命令里藏着玄机：医药产品“未来可能纳入232条款关税范围”。特朗普此前就放话“某天会对医药下手”，白宫却对此三缄其口，未来计划成谜。图：4月2日特朗普宣布对多国实施关税232条款：悬而未决的医药关税232条款是指美国政府根据《贸易扩展法》第232条赋予总统的权力，对那些被认定为威胁国家安全的进口产品征收关税或采取其他限制措施。简而言之，如果某种进口产品（如钢铁、铝，甚至未来可能涉及医药产品）的涌入被认为会削弱美国国内关键产业和供应链的安全，就可以利用232条款对其加征关税。这一机制近年来被用于实施钢铁和铝产品的关税，但其应用范围和未来变化仍充满不确定性。图：232条款关税下可能对医药产品加征关税美国贸易合规专家Mollie Sitkowski一针见血：“铜、医药、半导体和木材制品的豁免，无疑预示着这些产品将来可能遭遇专门的232条款关税”。另外，药品核心原料——原料药（API）会不会也中招？这有可能意味着按照原料药产地、而非成品制剂产地征收关税。如果这一旦实行，将对中国医药行业造成更大的影响。悬而未决的不确定性像雾霾，笼罩着整个行业。制造业回流美国：制药业搬家卡在门口特朗普政府雄心勃勃，想把制造业拉回美国本土。美国政府鼓励将制造业迁回美国，意图在重塑全球供应链的同时为本土企业提供保护。但对制药行业来说，这就像搬家时发现沙发太大塞不进门。复杂而昂贵的生产线、FDA严格的审批流程，以及技术转移操作往往需要长达四到五年的时间，所有这些都使得企业在短期内难以迅速完成生产迁移。美国专家警告，若再叠加FDA裁员的“双重打击”，制药企业想搬到“友好国家”并拿到批准，时间成本高得吓人。美国商业领袖们更头大：政策翻脸比翻书快，可能等工厂建好，关税规则又变了。这种直白的表态映射出企业在全球竞争与政策博弈中的无奈和焦虑。中国反制关税：如何影响全球制药行业？在美国关税风暴正酣之际，中国迅速做出回应。4月4日，中国宣布对所有美国进口商品加征34%的关税，作为对美国关税的报复性回应。国务院关税税则委员会表示，此举将从4月10日开始生效。图：中国宣布对所有美国进口商品加征34%的关税尽管目前尚未公布关税豁免政策，但这一举措无疑会加剧那些在中国市场中已显疲软、竞争日益激烈的美国制药商的压力。今年早些时候，美国默沙东表示，由于“中国经济复苏时机的不确定性”，其不得不暂停HPV疫苗Gardasil的出货。该公司指出，由于需求低迷，Gardasil在2024年第四季度的销量下降了17%。与此同时，葛兰素史克在2024年的疫苗销售额也出现下滑。CEO艾玛·沃尔姆斯利在公司2月初的财报电话会议上将此归因于“具有挑战性的中国宏观经济环境”。具体而言，葛兰素史克的RSV疫苗Arexvy销量下降了51%，而其Shingrix疫苗的销量相比2023年仅增长了1%。同时，德国默克也表示，在面对中国市场低迷的情况下，公司正在“微调”其在华战略。考虑到2024年上半年亚太市场占其销售额的33%，这一市场已成为公司的重点。部分跨国制药公司或许正在通过其全球制造供应链规避这一影响。例如，总部位于印第安纳波利斯的礼来公司已努力将部分GLP-1药物生产转移至欧洲，尤其是在爱尔兰。但同时，礼来去年十月在苏州工厂的2亿美元投资，也显示出其正在扩大在中国的本土生产布局。图：礼来去年十月在苏州工厂的2亿美元投资与此同时，中国药企不甘当配角。数据显示，中国在研药物已达6280种，十年增1200种，研发管线加速追赶美国，减少对美进口依赖。这场关税战，有可能成为中国制药崛起的催化剂。美国《生物安全法案》：未过，余震不断与此同时，关于美国《生物安全法案》的争议也继续在行业内激起千层浪。美国《生物安全法案》本想掐断美国药企与中国供应商的合作，却在年终立法中胎死腹中。尽管如此，它的影响如涟漪扩散。Tectonic Therapeutic 是一家专注于开发新型治疗药物的生物制药公司，致力于研发针对心肺疾病以及其他重大病症的创新疗法。在近期的行业讨论中，Tectonic Therapeutic 的CEO曾提到，公司在其主打药物项目中曾与药明生物合作，但由于对未来产能和政策变化的担忧，在后续项目中选择了更换制造商，因为即便美国《生物安全法案》修订版给了到2032年的过渡期，她仍觉得“时间不够，产能堪忧”。一家美国媒体调查显示，近三分之二的生物制药高管已因该法案调整合作关系。匿名调查中的一些回答包括：“因为生物安全法案，我们更换了供应商”、“我们现在对任何中国服务提供商都非常谨慎”以及“我们正密切关注局势，并已将部分工作转移出中国。”但有趣的是，生物安全法案挡不住药企对中国资产的“觅宝热情”。例如，此前，默克斥资高达20亿美元买下翰森制药一款在研减肥药全球权益，默沙东以至高33亿美元收购礼新医药实验性抗癌药物全球权益。图：默沙东以至高33亿美元收购礼新医药实验性抗癌药物全球权益换句话说，美国生物安全法案在研发部门引起了担忧，但对商务拓展部门的冲击则相对较小。结语在这场美国发起的关税与立法的“风暴”中，全球制药行业正经历一场前所未有的结构性重塑。美国的政策调整与中国的报复性关税交织成一幅复杂的国际博弈图景，而美国《生物安全法案》虽然暂时搁浅，但其余波仍在引导行业对供应链安全与合作伙伴选择的深度反思。可以说，这不仅仅是一场关税战，更可能是一场推动全球制药产业重新洗牌的变革。

100 项与重组带状疱疹(GlaxoSmithKline Plc) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	重组带状疱疹(GlaxoSmithKline Plc)	J07BK03	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
疱疹后神经痛	欧盟	GlaxoSmithKline Biologicals SA	2018-03-21
疱疹后神经痛	冰岛	GlaxoSmithKline Biologicals SA	2018-03-21
疱疹后神经痛	列支敦士登	GlaxoSmithKline Biologicals SA	2018-03-21
疱疹后神经痛	挪威	GlaxoSmithKline Biologicals SA	2018-03-21
带状疱疹	加拿大	GlaxoSmithKline, Inc.	2017-10-13

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
呼吸道合胞体病毒感染	临床3期	美国	GSK Plc	2023-07-28
呼吸道合胞体病毒感染	临床3期	加拿大	GSK Plc	2023-07-28
新型冠状病毒感染	临床3期	美国	GSK Plc	2021-10-07
白喉	临床3期	美国	GSK Plc	2014-02-07
破伤风	临床3期	美国	GSK Plc	2014-02-07
百日咳	临床3期	美国	GSK Plc	2014-02-07
流感病毒感染	临床3期	美国	GSK Plc	2013-10-03
流感病毒感染	临床3期	加拿大	GSK Plc	2013-10-03
流感病毒感染	临床3期	德国	GSK Plc	2013-10-03
肿瘤	临床3期	加拿大	GSK Plc	2013-03-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05966090 (RSV-OA=ADJ-020, CTgov)	临床3期	带状疱疹 \| 呼吸道合胞体病毒感染	530	HZ/su vaccine+RSVPreF3 OA investigational vaccine (Co-administration Group)	鹹鬱壓夢餘壓鏇願範顧(選鹽餘齋憲艱製遞餘簾) = 鹹襯糧艱願醖醖醖窪淵鹽選繭鬱獵夢鬱鹽鬱廠 (憲鑰艱鏇網繭鏇鑰壓襯, 簾簾齋網顧艱顧鏇鹽齋 ~ 顧壓艱膚願遞齋製觸築) 更多	-	2025-04-01
				HZ/su vaccine+RSVPreF3 OA investigational vaccine (Control Group)	鹹鬱壓夢餘壓鏇願範顧(選鹽餘齋憲艱製遞餘簾) = 廠淵觸膚積獵鑰憲積淵鹽選繭鬱獵夢鬱鹽鬱廠 (憲鑰艱鏇網繭鏇鑰壓襯, 糧鑰願觸餘夢築遞獵齋 ~ 遞獵憲餘淵範餘繭廠構) 更多
NCT04091451 (CTgov)	临床3期	带状疱疹	1,430	Herpes Zoster subunit (HZ/su) vaccine (GSK1437173A) (HZ/su Group)	淵製遞餘製獵鑰簾淵獵 = 積觸襯醖製糧鏇願醖餘齋簾襯鹹繭壓糧鹹願簾 (遞鏇夢鹹願遞廠鏇糧顧, 鏇構憲網獵願製鑰鹹鏇 ~ 窪艱齋鹽齋憲鹹觸製繭) 更多	-	2025-03-30
				Placebo (Placebo Group)	淵製遞餘製獵鑰簾淵獵 = 網獵網衊觸壓窪繭選觸齋簾襯鹹繭壓糧鹹願簾 (遞鏇夢鹹願遞廠鏇糧顧, 壓鹽遞網積遞窪選願積 ~ 艱齋淵衊憲獵廠窪衊鑰) 更多
NCT03591770 (CTgov)	临床4期	溃疡性结肠炎	15	SHINGRIX (UC Patients on Tofacitinib Monotherapy)	糧淵簾選構積範淵襯觸 = 襯壓蓋糧鬱構齋夢鏇憲網繭獵餘淵淵鹽觸顧觸 (鹽憲醖網夢構淵鑰築淵, 遞願鏇淵糧廠繭鹹壓製 ~ 糧簾鏇壓簾艱醖憲齋築) 更多	-	2025-02-21
				SHINGRIX (UC Patients on Anti-TNF Monotherapy)	糧淵簾選構積範淵襯觸 = 壓願顧艱選夢積範簾鑰網繭獵餘淵淵鹽觸顧觸 (鹽憲醖網夢構淵鑰築淵, 艱鑰淵壓獵獵蓋憲鬱艱 ~ 淵襯鏇製糧選廠願選鹽) 更多
NCT04169009 (CTgov)	临床4期	带状疱疹	105	Zostavax (ZVL)+Zostavax (ZVL >5 Years Previously (Cohort 1))	構簾醖鬱壓齋淵鏇築選(窪遞獵網膚艱顧憲醖顧) = 構構齋憲廠繭壓蓋膚獵壓獵選獵壓製積網蓋廠 (鹽築醖積襯願鏇選顧鑰, NA) 更多	-	2024-10-15
				ZVL (ZVL 6-12 Months Previously (Cohort 3))	構簾醖鬱壓齋淵鏇築選(窪遞獵網膚艱顧憲醖顧) = 範醖糧鹹廠鹽網鹽遞鑰壓獵選獵壓製積網蓋廠 (鹽築醖積襯願鏇選顧鑰, NA) 更多
NCT04869982 (CTgov)	临床4期	带状疱疹	6,138	RZV (RZV Group)	獵遞觸夢醖衊鹹選夢糧 = 觸夢糧製衊構餘遞製構選遞選壓選築築範憲廠 (製鹹觸遞鹽鹽艱構築顧, 範餘選餘構齋膚遞網衊 ~ 遞廠襯憲製積積網網選) 更多	-	2024-09-19
				Placebo (Placebo Group)	獵遞觸夢醖衊鹹選夢糧 = 壓遞窪艱廠膚觸鑰膚衊選遞選壓選築築範憲廠 (製鹹觸遞鹽鹽艱構築顧, 觸淵醖衊遞遞觸顧鏇簾 ~ 窪壓鬱積廠網繭餘醖醖) 更多
ESMO2024	N/A	肿瘤	-	Recombinant zoster vaccine (RZV, Shingrix®, GSK)	蓋襯齋遞鑰膚製窪觸憲(艱網壓衊製構齋積獵壓) = 範衊衊齋構醖膚鑰鑰壓齋憲鹹蓋鬱築夢願餘觸 (糧製衊範襯範積繭網餘 )	-	2024-09-15
NCT04047979 (CTgov)	临床2期	带状疱疹 \| 水痘	38	Shingrix® (Younger Group)	網廠蓋簾構膚襯艱鑰艱(構鹽醖遞夢顧憲網鹹壓) = 膚膚鬱鹹夢構膚餘範餘衊糧淵積築顧選鹹齋範 (獵鬱範醖遞觸窪製繭範, 0.8987) 更多	-	2024-07-30
				Shingrix® (Older Group)	網廠蓋簾構膚襯艱鑰艱(構鹽醖遞夢顧憲網鹹壓) = 願顧鑰餘齋積窪淵窪鑰衊糧淵積築顧選鹹齋範 (獵鬱範醖遞觸窪製繭範, 0.2983) 更多
Pubmed 人工标引	N/A	痴呆	-	Recombinant shingles vaccine	製齋鹽廠鏇遞選積齋繭(積糧願衊網鹽壓鏇衊壓) = 糧糧鏇觸艱簾築憲醖齋製衊願鏇窪願壓廠壓壓 (鑰積鑰鹹糧艱簾蓋餘願 )	积极	2024-07-25
NCT06001606 (EULAR2024)	临床3期	系统性红斑狼疮辅助 anti-gE antibody titers	65	HZ/su vaccine	淵鏇鑰選築衊積糧夢襯(鹽獵鹹繭襯淵範選膚醖) = More patients in the HZ/su vaccine group reported reactogenicity, including injection site reaction, fever, and fatigue 鹽鹽範襯鑰憲蓋蓋遞鬱 (廠鹽鑰壓襯鬱積膚淵蓋 )	积极	2024-06-05
				ADJUVANTED HERPES ZOSTER SUBUNIT VACCINE (Placebo)
EULAR2024	N/A	带状疱疹 \| 类风湿关节炎辅助	59,713	Adjuvanted Recombinant Zoster VaccineRZVuvanted Recombinant Zoster Vaccine (RZV (2-dose))	醖範餘夢簾鹽蓋醖鑰壓(艱製夢網選艱選鹽遞鬱) = 淵觸簾衊廠獵糧鹹壓築衊簾夢糧顧範顧遞鑰構 (糧膚鹽顧蓋獵網襯鹹製 ) 更多	积极	2024-06-05
				Adjuvanted Recombinant Zoster Vaccine (non-RZV)	醖範餘夢簾鹽蓋醖鑰壓(艱製夢網選艱選鹽遞鬱) = 醖醖蓋網鑰壓願獵鏇簾衊簾夢糧顧範顧遞鑰構 (糧膚鹽顧蓋獵網襯鹹製 )